Reports Outline Combination Therapy Study Results from China Pharmaceutical University (Nanoparticle delivery and combination therapy of gambogic acid and all-trans retinoic acid)
By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Drugs and Therapies. According to news reporting originating in Jiangsu, People's Republic of China, by NewsRx journalists, research stated, "In order to enhance the in vivo codelivery efficiency of gambogic acid (GA) and all-trans retinoic acid (ATRA), our strategy was to entrap GA in the self-assembled nanoparticles based on amphiphilic hyaluronic acid (HA)-ATRA (HRA) conjugate. In this way, GA and ATRA were loaded simultaneously in a nanocarrier and codelivered into the tumor cell through HA receptor-mediated endocytosis."
The news reporters obtained a quote from the research from China Pharmaceutical University, "GA-loaded HRA nanoparticles (GA-HRA) were prepared by a dialysis method, and their physicochemical characteristics were investigated as well. GA-HRA exhibited a high drug loading capacity (31.1%), had a particle size in the range of 100-150 nm, and good biocompatibility. HRA nanoparticles were effectively internalized by MCF-7 cells and translocated into the nucleus in a time-dependent manner. The in vivo imaging analysis demonstrated that the fluorescent signals in the tumor were markedly increased with DiR-loaded nanoparticles after intravenous administration compared to free DiR solution, suggesting it has excellent tumor targeting properties. More importantly, GA-HRA exhibited excellent in vivo efficacy with dramatically reduced toxicity."
According to the news reporters, the research concluded: "With the assistance of HRA nanoparticles, GA and ATRA can successfully realize an effective combination chemotherapy as well as tumor-targeted delivery."
For more information on this research see: Nanoparticle delivery and combination therapy of gambogic acid and all-trans retinoic acid. International Journal of Nanomedicine, 2014;9():3313-3324. International Journal of Nanomedicine can be contacted at: Dove Medical Press Ltd, PO Box 300-008, Albany, Auckland 0752, New Zealand (see also Drugs and Therapies).
Our news correspondents report that additional information may be obtained by contacting J. Yao, China Pharmaceutical University, State Key Lab Nat Med, Nanjing 210009, Jiangsu, People's Republic of China. Additional authors for this research include Y.K. Li, X.J. Sun, F.Z. Dahmani, H.P. Liu and J.P. Zhou.
Keywords for this news article include: Asia, Jiangsu, Nanoparticle, Nanotechnology, Combination Therapy, Drugs and Therapies, Emerging Technologies, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC